Co-Diagnostics (CODX) Expected to Announce Quarterly Earnings on Thursday

Co-Diagnostics (NASDAQ:CODX) is expected to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($3.00) per share and revenue of $0.1330 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Co-Diagnostics (NASDAQ:CODX) last released its quarterly earnings data on Thursday, May 14th. The company reported ($4.06) earnings per share for the quarter, missing the consensus estimate of ($3.75) by ($0.31). Co-Diagnostics had a negative net margin of 6,760.63% and a negative return on equity of 164.92%. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.13 million.

Co-Diagnostics Price Performance

NASDAQ:CODX opened at $1.50 on Tuesday. The company has a market cap of $5.54 million, a PE ratio of -0.10 and a beta of 2.88. Co-Diagnostics has a one year low of $1.26 and a one year high of $46.50. The firm’s 50 day simple moving average is $2.99 and its 200 day simple moving average is $2.70.

Analyst Upgrades and Downgrades

CODX has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Co-Diagnostics to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings lowered shares of Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $67.50.

Institutional Trading of Co-Diagnostics

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in shares of Co-Diagnostics by 40.4% in the 4th quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock worth $81,000 after buying an additional 129,158 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Co-Diagnostics by 314.1% during the second quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock valued at $47,000 after purchasing an additional 126,105 shares during the last quarter. Finally, Virtu Financial LLC raised its stake in Co-Diagnostics by 393.8% during the third quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock valued at $44,000 after buying an additional 100,901 shares during the last quarter. 14.99% of the stock is currently owned by hedge funds and other institutional investors.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.